Placebo News and Research

RSS

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

DCI receives FDA approval for PERTZYE NDA to treat EPI

Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Avraham initiates ladostigil Phase 2 trial in MCI

Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment.

18 May 2012

Kudzu root components may treat alcoholism and curb binge drinking

An extract of the Chinese herb kudzu dramatically reduces drinking and may be useful in the treatment of alcoholism and curbing binge drinking, according to a new study by McLean Hospital and Harvard Medical School researchers.

18 May 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

Most depressed patients must make multiple attempts before finding an effective antidepressant

UT Southwestern Medical Center psychiatrists are leading a national clinical trial to find biomarkers that can better predict how people suffering from depression will respond to medications so physicians eventually can personalize treatments.

16 May 2012

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults.

16 May 2012

Combination of vaccine and letrozole effectively improves survival from breast cancer

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice, a team of UC Davis investigators has found.

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

15 May 2012

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.

15 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Eli Lilly and Company will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.

15 May 2012

Menarini, Furiex enter license agreement to commercialize Priligy

Furiex Pharmaceuticals, Inc. and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East.

15 May 2012

Acupuncture may improve dyspnea in COPD patients

According to a small clinical trial reported by investigators from Japan, acupuncture appears to be associated with improvement of dyspnea (labored breathing) on exertion, in patients with chronic obstructive pulmonary disease (COPD), according to a study published Online First by Archives of Internal Medicine, a JAMA Network publication.

14 May 2012

Placebo News and Research

Sigmoid provides financial and product development update

DCI receives FDA approval for PERTZYE NDA to treat EPI

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Avraham initiates ladostigil Phase 2 trial in MCI

Kudzu root components may treat alcoholism and curb binge drinking

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Most depressed patients must make multiple attempts before finding an effective antidepressant

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Combination of vaccine and letrozole effectively improves survival from breast cancer

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Smoked cannabis may be an effective treatment for spasticity

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Menarini, Furiex enter license agreement to commercialize Priligy

Acupuncture may improve dyspnea in COPD patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News